Cowen and Leerink rated Quanterix at Outperform while JP Morgan initiated coverage with an Overweight rating — the banks managed the company's $74 million IPO.
The investment bank gave Exact Sciences' shares a price target of $30, and said it expects higher uptake of the Cologuard test and an increase in payor contracts.
The investment bank noted increased traction for Invitae's test, a "massive" market opportunity, and potential clinical and payor adoption of the firm's technology.
The investment bank said the quick approval by the FDA for T2 Bio's platform and Candida test could signal high interest for the product in the medical community.
NEW YORK (GenomeWeb News) – Leerink Swann today upgraded shares of Fluidigm, noting a potentially multi-billion market opportunity for single-cell gene expression tools and the recent acquisition of DVS Sciences as drivers.
The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.
